Corrigendum [0.03%]
勘误表
Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT) [0.03%]
复发性尿路感染的社会经济负担及对生活质量的影响：一项基于患者网络的调查（GESPRIT）研究
Florian Wagenlehner,Björn Wullt,Stefania Ballarini et al.
Florian Wagenlehner et al.
Background: Uncomplicated lower urinary tract infections (UTIs) occur in approximately 50% of women, and 20-30% experience recurrent UTI. Data on UTIs and quality of life (QoL) in Europe are limited. ...
Samantha N Steiger,Rachel R Comito,David P Nicolau
Samantha N Steiger
Urinary tract infections represent one of the most frequent reasons for hospitalization. As a result of their prevalence from community-based origins as well as those which develop in hospital setting, this constellation of infections repre...
Estimate of the cost of multiple sclerosis in Spain by literature review [0.03%]
西班牙多发性硬化症疾病负担的文献回顾及成本估算
Oscar Fernández,Miguel Angel Calleja-Hernández,José Meca-Lallana et al.
Oscar Fernández et al.
Multiple Sclerosis (MS) is a progressive disease leading to increasing disability and costs. A literature review was carried out to identify MS costs and to estimate its economic burden in Spain. Areas Covered: The public electronic databas...
Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder [0.03%]
共病注意缺陷多动障碍、情绪障碍和物质使用障碍的批判性探索
Judith Regnart,Ilse Truter,Anneke Meyer
Judith Regnart
Co-occurring disorders (CODs) describe a Substance Use Disorder (SUD) accompanied by a comorbid psychiatric disorder. Attention-Deficit/Hyperactivity Disorder (ADHD) and mood disorders are common CODs with high prevalence rates in SUD popul...
Micro factors bringing the pharmaceutical industry to a seismic shaking a qualitative research [0.03%]
微因素透视下的制药行业地震式变革定性研究报告
Raphaela Marie Louisa Dierks,Olivier Bruyère,Jean-Yves Reginster
Raphaela Marie Louisa Dierks
Introduction: Due to changing macro and micro factors, expiring patents and falling net income, pharmaceutical companies need to rethink their vertical business model. The trend shows cross-sectorial partnerships and cons...
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin [0.03%]
非瓣膜性房颤患者初服用达比加群或华法林的全因、卒中及出血特异的卫生资源利用比较研究
Xue Song,Pranav Gandhi,Adrienne M Gilligan et al.
Xue Song et al.
Background: We compared healthcare utilization outcomes and persistence among non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran or warfarin. ...
Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs [0.03%]
基于药学成本的转移性野生型ras结直肠癌一线使用表皮生长因子受体抑制剂的观点分析
Jacopo Giuliani,Andrea Bonetti
Jacopo Giuliani
In light of the relevant expenses of pharmacological interventions it might be interesting to make a balance between the cost of the new drugs administered, such as EGFRIs (cetuximab and panitunumab) and the added value represented by the i...
Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective [0.03%]
从西班牙国家卫生系统角度分析德谷胰岛素与甘精胰岛素u100治疗1型和2型糖尿病的性价比研究
Pedro Mezquita-Raya,Josep Darbà,Meritxell Ascanio et al.
Pedro Mezquita-Raya et al.
Background: The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. ...
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel [0.03%]
欧洲医学肿瘤学会的临床效益规模在以色列抗癌药物报销决策中的应用分析
Ariel Hammerman,Sari Greenberg-Dotan,Ilan Feldhamer et al.
Ariel Hammerman et al.
Background: The European Society for Medical Oncology published in 2015 its Magnitude of Clinical Benefit Scale (ESMO-MCBS) for cancer medicines. Our objective was to evaluate the association between Israel's national rei...